Brief: China Biotech Services Says SDCL & BGI Entered Supplemental Master Supply Deal To Increase 2022 Annual Cap From Hk$80 Million To HK$400 Mln For Year
15/02/2022 15:25
Feb 15 (Reuters) - China Biotech Services Holdings Ltd
8037.HK :
* SDCL & BGI ENTERED SUPPLEMENTAL MASTER SUPPLY DEAL TO
INCREASE
2022 ANNUAL CAP FROM HK$80 MILLION TO HK$400 MILLION FOR YEAR
* AS AT FEB 15, BGI HOLDS 40% OF ISSUED SHARE CAPITAL OF
SDCL, AN
INDIRECT 60%-CONTROLLED UNIT OF CO
Further company coverage: 8037.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on China Biotech Services Holdings
See all newsBrief: China Biotech Services Enters Cooperation Agreement
Brief: China Biotech Services Says HY Revenue From Cont Ops Hk$37.23 Million
Brief: China Biotech Services Expects HY Net Profit Of Not Less Than HK$15.0 MLN
Brief: China Biotech Services Enters Master Collaboration Agreement With Stella Pharma
Brief: China Biotech Services Says BGI Songhe Advances RMB30 Million Loan To Pengbo (Hainan)